Talk Bio

Maze Therapeutics announced positive topline data from the Phase 2 HORIZON trial of MZE829 on March 25, 2026, showing a 35.6% mean reduction in urinary albumin-to-creatinine ratio (uACR) at week 12 in broad APOL1-mediated kidney disease (AMKD) patients, with 50% achieving >30% reduction. 1 2 3 In subgroups, MZE829 achieved a 61.8% mean uACR reduction in FSGS patients and 48.6% in non-diabetic AMKD patients; treatment was well-tolerated with no serious adverse events. 1 3 This marks the first clinical proof-of-concept for MZE829 in broad AMKD, including patients with moderate proteinuria and diabetes; Maze plans to advance to a pivotal program. 1 3 The trial positions Maze to compete with Vertex in APOL1 kidney disease treatments. 2 Sources: 1. https://www.globenewswire.com/news-release/2026/03/25/3262076/0/en/Maze-Therapeutics-Announces-Positive-Topline-Data-from-Phase-2-HORIZON-Trial-of-MZE829-Demonstrating-the-First-Clinical-Proof-of-Concept-in-Patients-with-Broad-APOL1-...